FREMONT, Calif. — Neuralink is shifting its brain-computer interface from clinical-scale production to an industrialized manufacturing model, with Elon Musk announcing the transition on December 31, 2025. At the center of the upgrade is the company's R1 surgical robot, now capable of implanting the N1 device through the dura without requiring its removal.
The Technical Breakthrough
Earlier Neuralink procedures required partial excision of the dura mater — the tough protective membrane covering the brain and spinal cord — before the implant's electrode threads could be inserted. The R1 robot's updated process threads directly through the dura, eliminating that step entirely.
"Device threads will go through the dura, without the need to remove it," Musk wrote on X. "This is a big deal."
The practical significance is twofold. First, bypassing dural removal reduces surgical invasiveness and lowers the risk of intracranial infection or trauma. Second, a fully automated procedure is repeatable at scale in a way that surgeon-dependent surgery is not — a prerequisite for any high-volume implant program.
Patients and Clinical Progress
By early 2026, the number of Neuralink trial participants had grown to approximately 20 — up from 12 in September 2025. Current patients, who have severe paralysis or ALS, are actively using the implant to control computer cursors and robotic arms through thought alone, demonstrating the practical utility the device delivers for people who have lost motor function.
The company raised USD 650 million in a Series E funding round, pushing its estimated valuation to USD 9 billion. That capital is supporting both the production ramp and an expansion of clinical trials beyond the United States to Canada, the United Kingdom, Germany, and the UAE.
The Vision Behind Mass Production
Neuralink's long-term goal is not a small clinical population of implant users — it is a world where brain-computer interfaces are a routine medical tool for anyone with a neurological injury or disease. Getting there requires volume: manufacturing thousands, eventually tens of thousands, of N1 devices per year at consistent quality, paired with surgical procedures that can be performed at hospitals rather than exclusively at specialized centers.
The move to automated surgery is the enabling step for that vision. An R1 robot can perform the same procedure with the same precision across any facility equipped to receive it, removing the geographic and skills bottleneck that limits how quickly the technology can reach patients in need.
Blindsight and Beyond
While the N1 implant scales up for motor and communication applications, Neuralink's second device — Blindsight — is advancing through early clinical trials in the UAE, where it received regulatory approval in early June 2026. Blindsight targets vision restoration for patients who are completely blind, representing an entirely separate application of the company's electrode insertion platform.
Together, the N1 production ramp and the Blindsight trial expansion represent a Neuralink operating at a different scale than the one that performed its first human implant in January 2024 — and one that appears to be accelerating on every front.
